Cargando…

Assessing Variation in the Cost of Palivizumab for Respiratory Syncytial Virus Prevention in Preterm Infants

BACKGROUND: The variability in cost of palivizumab treatment, indicated for prevention of respiratory syncytial virus (RSV) infections in high-risk infants, has not been robustly estimated in prior studies. This study aimed to determine the cost variations of palivizumab from a US payer perspective...

Descripción completa

Detalles Bibliográficos
Autores principales:	Shahabi, Ahva, Peneva, Desi, Incerti, Devin, McLaurin, Kimmie, Stevens, Warren
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2017
Materias:	Original Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5820240/ https://www.ncbi.nlm.nih.gov/pubmed/29464672 http://dx.doi.org/10.1007/s41669-017-0042-3

Ejemplares similares

The Medicaid Cost of Palivizumab
por: Ambrose, Christopher S., et al.
Publicado: (2015)

Trends in Utilization of Outpatient Respiratory Syncytial Virus Prophylaxis with Palivizumab among Medicaid- and Commercially Insured Infants
por: Pavilack, Melissa, et al.
Publicado: (2017)

Palivizumab Prophylaxis for Respiratory Syncytial Virus: Examining the Evidence Around Value
por: Olchanski, Natalia, et al.
Publicado: (2018)

Modeling the Potential Impact of the 2014 American Academy of Pediatrics Respiratory Syncytial Virus Prophylaxis Guidance on Preterm Infant RSV Outcomes
por: McLaurin, Kimmie K., et al.
Publicado: (2015)

Impact of Respiratory Syncytial Virus–Confirmed Hospitalizations on Caregivers of US Preterm Infants
por: Pokrzywinski, Robin M., et al.
Publicado: (2019)

Respiratory syncytial virus hospitalization outcomes and costs of full-term and preterm infants
por: McLaurin, K K, et al.
Publicado: (2016)

Chronologic Age at Hospitalization for Respiratory Syncytial Virus Among Preterm and Term Infants in the United States
por: Parikh, Rohan C., et al.
Publicado: (2017)

Effectiveness of palivizumab immunoprophylaxis in preterm infants against respiratory syncytial virus disease in Qatar
por: Abushahin, Ahmad, et al.
Publicado: (2018)

Population-based trends and underlying risk factors for infant respiratory syncytial virus and bronchiolitis hospitalizations
por: Bennett, Mihoko V., et al.
Publicado: (2018)

Hospitalizations in the First Year of Life for Infants with Respiratory Syncytial Virus and Unspecified Bronchiolitis in a Population-Based Cohort
por: Lee, Henry, et al.
Publicado: (2017)

Cost-utility analysis of Palivizumab for Respiratory Syncytial Virus infection prophylaxis in preterm infants: update based on the clinical evidence in Spain
por: Sanchez-Luna, M., et al.
Publicado: (2017)

The 2014–2015 National Impact of the 2014 American Academy of Pediatrics Guidance for Respiratory Syncytial Virus Immunoprophylaxis on Preterm Infants Born in the United States
por: Kong, Amanda M., et al.
Publicado: (2018)

Respiratory Syncytial Virus Hospitalizations among U.S. Preterm Infants Compared with Term Infants Before and After the 2014 American Academy of Pediatrics Guidance on Immunoprophylaxis: 2012–2016
por: Goldstein, Mitchell, et al.
Publicado: (2018)

Trends in Respiratory Syncytial Virus and Bronchiolitis Hospitalization Rates in High-Risk Infants in a United States Nationally Representative Database, 1997–2012
por: Doucette, Abigail, et al.
Publicado: (2016)

Review of palivizumab in the prophylaxis of respiratory syncytial virus (RSV) in high-risk infants
por: Mejías, Asunción, et al.
Publicado: (2008)

Respiratory Syncytial Virus Infection in High-risk Infants – an Update on Palivizumab Prophylaxis
por: Resch, Bernhard
Publicado: (2014)

Human respiratory syncytial virus and other viral infections in infants receiving palivizumab
por: Boivin, Guy, et al.
Publicado: (2008)

Utilization Management Opportunities for Palivizumab for Prophylaxis of Respiratory Syncytial Virus Complications in Infants
por: Curtiss, Frederic R., et al.
Publicado: (2010)

Should we use Palivizumab immunoprophylaxis for infants against respiratory syncytial virus? – a cost-utility analysis
por: Ginsberg, Gary M., et al.
Publicado: (2018)

Respiratory syncytial virus and palivizumab prophylaxis in the COVID-19 era
por: Taylor, Richard S.
Publicado: (2021)

Palivizumab Compliance by Infants in Puerto Rico During the 2009–2010 Respiratory Syncytial Virus Season
por: Matías, Israel, et al.
Publicado: (2014)

Cost-utility analysis of palivizumab in Italy: results from a simulation model in the prophylaxis of respiratory syncytial virus infection (RSV) among high-risk preterm infants
por: Chirico, Gaetano, et al.
Publicado: (2009)

Respiratory Syncytial Virus Prophylaxis in Infants With Congenital Diaphragmatic Hernia in the Canadian Respiratory Syncytial Virus Evaluation Study of Palivizumab, 2005–2017
por: Kim, Doyoung, et al.
Publicado: (2019)

Serum palivizumab level is associated with decreased severity of respiratory syncytial virus disease in high-risk infants
por: Forbes, Michael L, et al.
Publicado: (2014)

Revised recommendations concerning palivizumab prophylaxis for respiratory syncytial virus (RSV)
por: Bollani, Lina, et al.
Publicado: (2015)

A Novel Six Consecutive Monthly Doses of Palivizumab Prophylaxis Protocol for the Prevention of Respiratory Syncytial Virus Infection in High-Risk Preterm Infants in Taiwan
por: Chi, Hsin, et al.
Publicado: (2014)

Respiratory syncytial virus associated hospitalizations in preterm infants of 29 to 32 weeks gestational age using a risk score tool for palivizumab prophylaxis
por: Resch, B., et al.
Publicado: (2017)

Palivizumab: a review of its use in the protection of high risk infants against respiratory syncytial virus (RSV)
por: Geskey, Joseph M, et al.
Publicado: (2007)

Guidelines for palivizumab prophylaxis in infants and young children at increased risk for respiratory syncytial virus infection in Saudi Arabia
por: Al Aql, Fahad, et al.
Publicado: (2016)

Respiratory syncytial virus-neutralizing serum antibody titers in infants following palivizumab prophylaxis with an abbreviated dosing regimen
por: Claydon, Jennifer, et al.
Publicado: (2017)

Risk Factors for Hospitalization due to Lower Respiratory Tract Infection in Preterm Infants on Palivizumab Prophylaxis
por: Oncel, Mehmet Yekta, et al.
Publicado: (2013)

Product review on the monoclonal antibody palivizumab for prevention of respiratory syncytial virus infection
por: Resch, Bernhard
Publicado: (2017)

Effectiveness of palivizumab in preventing respiratory syncytial virus infection in high-risk children
por: Viguria, Natividad, et al.
Publicado: (2021)

National Bronchiolitis Hospitalization Rates Among Preterm and Full Term Infants: 2010–2015
por: Krilov, Leonard R, et al.
Publicado: (2017)

A comparative study of respiratory syncytial virus (RSV) prophylaxis in premature infants within the Canadian Registry of Palivizumab (CARESS)
por: Paes, B., et al.
Publicado: (2012)

Evaluation of respiratory complications in a cohort of preterm infants who did not receive palivizumab monoclonal antibodies
por: Bonati, Poliana Castro de Resende, et al.
Publicado: (2022)

Palivizumab use during respiratory syncytial virus outbreak in the neonatal intensive care unit
por: Alan, S., et al.
Publicado: (2012)

Aerosol Delivery of Palivizumab in a Neonatal Lamb Model of Respiratory Syncytial Virus Infection
por: Edirisinghe, Hasindu S., et al.
Publicado: (2023)

Characteristics and health care utilization of otherwise healthy commercially and Medicaid-insured preterm and full-term infants in the US
por: McLaurin, Kimmie K, et al.
Publicado: (2019)

Risk factors for recurrent wheezing in preterm infants who received prophylaxis with palivizumab
por: Manini, Mariana Bueno, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_tvmg2salrcmc4qk3n1ekeb18ll